The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.
Voluntary signing of informed consent form;
Liver and kidney function: Blood bilirubin ≤ 35 μ mol/L, AST/ALT < 2 times the upper limit of normal, blood creatinine ≤ 150 μ mol/L;
Normal heart function (EF ≥ 50%, NYHA I/II);
Physical condition score 0-2 (ECOG score);
Acute promyelocytic leukemia;
Hematological non-remisssion or recurrence;
Uncontrolled infection or grade 3-4 graft-versus-host disease (GVHD);
Allergies or contraindications to any of the drugs involved in the protocol;